HUGroup Holdings (4544) AI Stock Analysis

• Market Cap: ¥198.95B
• Dividend Yield: 3.59%
• Average Volume (3M): 322.37K
• Price to Earnings (P/E): 142.5
• Beta (1Y): 0.46
• Revenue Growth: 2.15%
• EPS Growth: N/A
• Country: JP
• Employees: 5,295
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -21.08
• Shares Outstanding: 57,476,124
• 10 Day Avg. Volume: 421,790
• 30 Day Avg. Volume: 322,366
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥2,299.39
• Price Target Upside: -34.02% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 1

• Rating: 56 Neutral
• Price Target: ¥3,489.00 ▲(0.11% Upside)

HUGroup Holdings' overall stock score is primarily influenced by its financial performance, which shows signs of operational recovery and a strong equity base. However, technical analysis indicates short-term bearish momentum, and the high P/E ratio raises valuation concerns. The dividend yield provides some compensation for the high valuation, but the lack of earnings call and corporate events data limits additional insights.

HUGroup Holdings Business Overview & Revenue Model

Company Description

H.U. Group Holdings, Inc., through its subsidiaries, provides laboratory testing products and services in Japan. The company offers lab testing and its related services to medical institutions; self-medication services; food, environment, and cosmetic testing services; and testing services through corporate health insurance associations. It also researches, develops, manufactures, and sells in vitro diagnostic devices, which includes the LUMIPULSE, an automatic chemiluminescent enzyme immunoassay system that offers reagents for infectious disease, cancer, and lifestyle disease to medical institutions and testing centers; and ESPRINE, a rapid diagnostics kit series for influenza, hepatitis B, and the novel coronavirus, as well as supplies ingredients for test drugs. In addition, the company provides support services related to hospital administration work, including aid for surgical procedures and endoscope room work, inspection and maintenance services for medical equipment, and in-hospital logistics management and transportation services; and rents and sells nursing-care equipment and supplies. Further, it offers home-visit nursing care services. The company was formerly known as Miraca Holdings Inc. and changed its name to H.U. Group Holdings, Inc. in July 2020. H.U. Group Holdings, Inc. was incorporated in 1950 and is headquartered in Tokyo, Japan.

How the Company Makes Money

HUGroup Holdings generates revenue through several key streams. The company earns money by selling medical devices and diagnostic equipment to healthcare facilities and laboratories. Another significant revenue stream comes from providing laboratory testing services, which includes various clinical tests and diagnostic analyses for medical institutions. Additionally, HUGroup Holdings may engage in partnerships or collaborations with other healthcare organizations to expand its service offerings and increase market reach, contributing to its overall earnings. The company leverages its expertise in medical technology and diagnostics to maintain a competitive edge in the healthcare market.

HUGroup Holdings Financial Statement Overview

Summary

HUGroup Holdings is navigating through a phase of recovery with improving operating margins and a robust equity base. While revenue growth has been modest, the recovery in EBIT and EBITDA margins suggests operational improvements. The balance sheet remains strong, although rising debt levels warrant attention. Cash flow management appears to be improving, but past volatility suggests the need for cautious cash flow strategies moving forward.

Income Statement

HUGroup Holdings has shown fluctuating revenue trends with a recent annual growth rate of 2.56%. Gross profit margins have been relatively stable, averaging around 27% over the years, but there was a significant dip in net income during 2024. The company has managed to recover its EBIT and EBITDA margins in 2025, indicating some operational recovery.

Balance Sheet

The company's balance sheet reflects strong equity, with a moderate debt-to-equity ratio of 0.63 in 2025. There is a consistent high equity ratio averaging around 48%, indicating a strong capital base. However, the increase in total debt over the years suggests a potential leverage risk.

Cash Flow

HUGroup Holdings has seen volatility in its free cash flow, with a significant recovery in 2025 after a negative free cash flow in 2024. The operating cash flow to net income ratio is robust, indicating efficient cash generation relative to net income. However, the fluctuations in free cash flow highlight potential cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	243.03B	243.03B	236.95B	260.91B	272.94B	223.02B
Gross Profit	66.94B	66.72B	63.23B	89.92B	111.80B	76.21B
EBITDA	23.29B	24.55B	13.65B	43.08B	65.12B	37.89B
Net Income	2.73B	2.76B	-7.55B	15.68B	29.60B	17.47B
Balance Sheet
Total Assets	279.58B	279.58B	290.85B	297.92B	286.59B	252.75B
Cash, Cash Equivalents and Short-Term Investments	40.88B	40.88B	39.95B	44.41B	46.71B	43.76B
Total Debt	86.65B	86.65B	81.94B	77.16B	73.00B	80.45B
Total Liabilities	142.28B	142.28B	148.34B	147.88B	146.41B	137.45B
Stockholders Equity	137.29B	137.29B	142.50B	150.04B	140.18B	115.31B
Cash Flow
Free Cash Flow	17.88B	17.88B	-1.01B	10.85B	20.10B	14.40B
Operating Cash Flow	21.96B	21.96B	16.55B	32.53B	55.23B	35.59B
Investing Cash Flow	-15.96B	-15.96B	-16.05B	-29.58B	-30.86B	-28.27B
Financing Cash Flow	-5.30B	-5.30B	-5.78B	-5.76B	-21.73B	-1.57B

HUGroup Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3485.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4544, the sentiment is Neutral. The current price of 3485 is below the 20-day moving average (MA) of 3656.75, above the 50-day MA of 3429.48, and above the 200-day MA of 2899.34, indicating a neutral trend. The MACD of 40.13 indicates Positive momentum. The RSI at 44.56 is Neutral, neither overbought nor oversold. The STOCH value of 26.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4544.

HUGroup Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4694	78 Outperform	149.39B	22.27	4.84%	2.71%	5.31%	7.90%
9776	74 Outperform	3.85B	7.38	4.16%	2.04%	2.23%	12.02%
4886	68 Neutral	63.47B	13.34	7.81%	2.10%	6.23%	-31.45%
4671	67 Neutral	25.95B	13.60	7.60%	4.75%	1.01%	13.91%
4549	63 Neutral	78.31B	35.73	5.11%	2.16%	3.80%	6.68%
4544	56 Neutral	¥198.95B	142.48	0.95%	3.59%	2.15%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

HUGroup Holdings Corporate Events

H.U. Group Transfers Majority Stake in Care’x to Wakita

H.U. Group Holdings has decided to transfer 80% of its shares in Care’x Inc. to Wakita & Co., aiming to enhance Care’x’s growth potential by leveraging Wakita’s strategic investments in the nursing care market. This move aligns with H.U. Group’s strategy to improve capital efficiency and focus on investment returns, while Care’x will benefit from Wakita’s expertise and resources to navigate the competitive welfare equipment rental market.

The most recent analyst rating on (JP:4544) stock is a Hold with a Yen3927.00 price target. To see the full list of analyst forecasts on HUGroup Holdings stock, see the JP:4544 Stock Forecast page.

H.U. Group Holdings Reports No Treasury Stock Acquisitions

H.U. Group Holdings announced that despite a resolution to acquire up to 2,500,000 of its own shares, no shares were acquired during the specified period from August 1 to August 29, 2025. This decision, initially resolved at a Board of Directors meeting in May 2025, was intended to be executed through market purchases on the Tokyo Stock Exchange, with a total acquisition cost of up to ¥5 billion. The lack of acquisition could impact the company’s stock valuation and shareholder expectations.

The most recent analyst rating on (JP:4544) stock is a Hold with a Yen3927.00 price target. To see the full list of analyst forecasts on HUGroup Holdings stock, see the JP:4544 Stock Forecast page.

H.U. Group Holdings Reports Q1 2025 Financial Results with Optimistic Outlook

H.U. Group Holdings reported its consolidated financial results for the three months ending June 30, 2025, showing a 3.2% increase in net sales compared to the previous year. Despite the rise in sales, the company faced a loss attributable to owners of the parent, indicating challenges in profitability. The financial outlook for the fiscal year ending March 31, 2026, remains optimistic with expected growth in net sales and operating profit, suggesting a potential recovery in the company’s financial performance.

The most recent analyst rating on (JP:4544) stock is a Hold with a Yen2700.00 price target. To see the full list of analyst forecasts on HUGroup Holdings stock, see the JP:4544 Stock Forecast page.

H.U. Group Holdings Reports No Treasury Stock Acquisition

H.U. Group Holdings announced that it did not acquire any treasury stock during the specified period from July 1 to July 31, 2025, despite a prior resolution to purchase up to 2,500,000 shares. This lack of acquisition may impact the company’s stock market strategy and shareholder value, as the intended market purchases were not executed.

The most recent analyst rating on (JP:4544) stock is a Hold with a Yen3000.00 price target. To see the full list of analyst forecasts on HUGroup Holdings stock, see the JP:4544 Stock Forecast page.

H.U. Group Holdings Reports No Treasury Stock Acquisition in June

H.U. Group Holdings announced that it has not acquired any of its treasury stock during the specified period from June 1, 2025, to June 30, 2025, despite a prior resolution to acquire up to 2,500,000 shares. The acquisition was intended to be conducted through market purchases on the Tokyo Stock Exchange, but no shares were acquired, impacting the company’s stock repurchase strategy.

The most recent analyst rating on (JP:4544) stock is a Hold with a Yen2700.00 price target. To see the full list of analyst forecasts on HUGroup Holdings stock, see the JP:4544 Stock Forecast page.